{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:06:15Z","timestamp":1790132775066,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"True North Therapeutics"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jid.2019.04.025","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T18:51:20Z","timestamp":1561056680000},"page":"2417-2424.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Specific Inhibition of the Classical Complement\u00a0Pathway Prevents C3 Deposition\u00a0along the Dermal-Epidermal Junction in Bullous\u00a0Pemphigoid"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8916-9782","authenticated-orcid":false,"given":"Patricia Colchete","family":"Freire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-2510","authenticated-orcid":false,"given":"Cristina Herraez","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9944-8483","authenticated-orcid":false,"given":"Ulla","family":"Derhaschnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2286-1077","authenticated-orcid":false,"given":"Christian","family":"Schoergenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1927-4936","authenticated-orcid":false,"given":"Christa","family":"Firbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3009-4947","authenticated-orcid":false,"given":"Graham C.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7901-2730","authenticated-orcid":false,"given":"Sandip","family":"Panicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-9447","authenticated-orcid":false,"given":"James C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3843-7841","authenticated-orcid":false,"given":"Georg","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-7977","authenticated-orcid":false,"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4326-2871","authenticated-orcid":false,"given":"Peter Maximilian","family":"Heil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2019.04.025_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/cpt.1111","article-title":"A\u00a0Randomized, first-in-human, Healthy Volunteer Trial of sutimlimab, a Humanized antibody for the Specific Inhibition of the Classical Complement Pathway","volume":"104","author":"Bartko","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2019.04.025_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fmed.2018.00238","article-title":"Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing literature","volume":"5","author":"Bech","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jid.2019.04.025_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-144-4-200602210-00007","article-title":"Brief communication: better ways to question patients about adverse medical events: a randomized, controlled trial","volume":"144","author":"Bent","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jid.2019.04.025_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2133.2011.10413.x","article-title":"Autoimmune Bullous Disease Swiss Study Group. Mortality of bullous pemphigoid in Switzerland: A prospective study","volume":"165","author":"Cort\u00e9s","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13023-016-0494-z","article-title":"Combined integrated protocol\/basket trial design for a first-in-human trial","volume":"11","author":"Derhaschnig","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2019.04.025_bib7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in- patient phase 1 trial","volume":"14","author":"Eskandary","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jid.2019.04.025_bib8","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/bjd.15924","article-title":"IgE auto-reactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants","volume":"177","author":"Freire","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1523-1747.ep12507222","article-title":"An in\u00a0vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement","volume":"78","author":"Gammon","year":"1982","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/1523-1747.ep12521246","article-title":"Leukocyte chemotaxis to the dermal-epidermal junction of human skin mediated by pemphigoid antibody and complement: mechanism of cell attachment in the in\u00a0vitro leukocyte attachment method","volume":"76","author":"Gammon","year":"1981","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1126\/science.1718035","article-title":"Suppression of the immune response by a soluble complement receptor of B lymphocytes","volume":"254","author":"Hebell","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.jid.2019.04.025_bib12","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1074\/jbc.M111.221036","article-title":"The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid","volume":"286","author":"Heimbach","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2019.04.025_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1084\/jem.172.2.665","article-title":"In\u00a0vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody","volume":"172","author":"Heyman","year":"1990","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2019.04.025_bib14","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany","volume":"136","author":"H\u00fcbner","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial","volume":"133","author":"J\u00e4ger","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.04.025_bib15","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib16","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A\u00a0comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A\u00a0comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2019.04.025_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3389\/fimmu.2018.00488","article-title":"Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2","volume":"9","author":"Karsten","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2019.04.025_bib19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jid.2017.08.030","article-title":"The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies","volume":"138","author":"Kasprick","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.jid.2019.04.025_bib21","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jid.2019.04.025_bib22","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.1000667","article-title":"Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model","volume":"185","author":"Li","year":"2010","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.jid.2019.04.025_bib23","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1172\/JCI116856","article-title":"A\u00a0passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180","volume":"92","author":"Liu","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2019.04.025_bib24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2019.04.025_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2019.04.025_bib26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/ced.12831","article-title":"Current practice in treatment approach for bullous pemphigoid: comparison between national surveys from the Netherlands and the UK","volume":"41","author":"Meijer","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fimmu.2018.00535","article-title":"Specific inhibition of complement activation significantly ameliorates autoimmune blistering disease in mice","volume":"9","author":"Mihai","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2019.04.025_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-4632.2009.04322.x","article-title":"Prevention and treatment of systemic glucocorticoid side effects","volume":"49","author":"Moghadam-Kia","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib29","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1097\/TP.0000000000001804","article-title":"Blockade of HLA antibody-triggered classical complement activation in sera from subjects dosed with the anti-C1s monoclonal antibody TNT009 - results from a randomized first-in-human phase 1 trial","volume":"101","author":"M\u00fchlbacher","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jid.2019.04.025_bib30","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.4049\/jimmunol.1003402","article-title":"Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner","volume":"188","author":"Natsuga","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2019.04.025_bib31","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1172\/JCI17891","article-title":"Role of different pathways of the complement cascade in experimental bullous pemphigoid","volume":"116","author":"Nelson","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2019.04.025_bib32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.13648","article-title":"Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor","volume":"173","author":"Peerschke","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jid.2019.04.025_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archinte.166.2.155","article-title":"Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects","volume":"166","author":"Rief","year":"2006","journal-title":"Arch Intern Med, (United States)"},{"key":"10.1016\/j.jid.2019.04.025_bib34","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jid.2019.04.025_bib35","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/ajt.13273","article-title":"An anti-C1s monoclonal, TNT003, inhibits complement activation induced by antibodies against HLA","volume":"15","author":"Thomas","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jid.2019.04.025_bib36","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2019.04.025_bib37","first-page":"1077","article-title":"Diagnosis of autoimmune bullous diseases","volume":"16","author":"van Beek","year":"2018","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jid.2019.04.025_bib38","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British Association of Dermatologists\u2019 guidelines for the management of bullous pemphigoid 2012","volume":"167","author":"Venning","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2019.04.025_bib39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.0022-202x.2001.01683.x","article-title":"Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid","volume":"118","author":"Yamamoto","year":"2002","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X1931783X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X1931783X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:15:41Z","timestamp":1758302141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X1931783X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0022202X1931783X"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2019.04.025","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specific Inhibition of the Classical Complement\u00a0Pathway Prevents C3 Deposition\u00a0along the Dermal-Epidermal Junction in Bullous\u00a0Pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2019.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}